Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 3/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521704 | 1.00 | TLR2 (0.51) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL31493934 | 1.00 | TLR2 (0.51) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL5312217 | 1.00 | TLR2 (0.51) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL29400519 | 1.00 | TLR2 (0.51) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL30546904 | 0.97 | TLR2 (0.48) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL12852250 | 0.97 | TLR2 (0.49) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL29531876 | 0.97 | TLR2 (0.54) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL16925663 | 0.92 | KMT2A (0.53) | TLR2TLR1MDM2KMT2AMDM4 | |
| SCHEMBL19718318 | 0.89 | TLR2 (0.44) | TLR2TLR1MDM2KMT2AKLK7 | |
| SCHEMBL20435349 | 0.89 | KMT2A (0.52) | TLR2TLR1MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | disclosed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | COMELL UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3883610-A1 | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER | Cornell University (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210128757-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2020-12-31 | — | — | US | disclosed |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | disclosed |
| US-20180299462-A1 | Methods for Enriching Glycopeptides for Global Analysis of Glycoproteins | NATIONAL SCIENCE FOUNDATION | 2018-10-18 | — | — | US | disclosed |
| WO-2018187631-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2018-10-11 | — | — | WO | disclosed |
| US-9290791-B2 | Reagents and methods for sirtuin capture | CORNELL UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-8288351-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8278280-B2 | Antagonists of the bradykinin B1 receptor | AMGEN INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-7605120-B2 | peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | AMGEN INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285227-B2 | Trifunctional constructs with tunablepharmacokinetics useful in imaging and anti-tumor therapies | MC2R, OGFR, GLS | TLR2 4118/4885TLR1 3839/4885MDM2 1763/4885 |
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-20090048149-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | TLR2 188/4885TLR1 69/4885MDM2 1683/4885 |
| US-20210128757-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLEPHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | MC2R, OGFR, GLS | TLR2 4118/4885TLR1 3839/4885MDM2 1763/4885 |
| US-20230114130-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, KRAS | TLR2 4003/4885TLR1 3865/4885MDM2 796/4885 |
| US-20090137452-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, LTB4R | TLR2 205/4885TLR1 93/4885MDM2 1653/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-20090137483-A1 | Antagonists of the bradykinin B1 receptor | BDKRB1, BDKRB2, AVPR1B | TLR2 140/4885TLR1 79/4885MDM2 1443/4885 |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-12377175-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-12268759-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | TLR2 4148/4885TLR1 4326/4885MDM2 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.